Cabotegravir Long Acting for HIV Prevention: 2023 Innovating for Impact Partnership Award honoree
Channel: GHTC
Date: 13/12/2023

Introducing cabotegravir long acting (CAB-LA) for HIV prevention as GHTC's 2023 Innovating for Impact Partnership Award honoree. As the first and only long acting injectable HIV prevention option available, CAB-LA is a game-changing product that could help more people use and adhere to PrEP, ultimately transforming global HIV prevention efforts.